MILLA, MONICA

MILLA, MONICA  

Mostra records
Risultati 1 - 13 di 13 (tempo di esecuzione: 0.018 secondi).
Titolo Data di pubblicazione Autore(i) File
Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. 2013 Matucci A; Pratesi S; Petroni G; Nencini F; Virgili G; Milla M; Maggi E; Vultaggio A.
Applicability of the International Bowel Ultrasound Segmental Activity Score (IBUS-SAS) to ulcerative colitis: a preliminary study 2024 Innocenti, Tommaso; Rocco, Carmen; Lynch, Erica Nicola; Milla, Monica; Galli, Andrea; Dragoni, Gabriele
Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions 2016 Vultaggio A.; Petroni G.; Pratesi S.; Nencini F.; Cammelli D.; Milla M.; Prignano F.; Annese V.; Romagnani S.; Maggi E.; Matucci A.
Clinical characteristics of psoriasis in inflammatory bowel disease patients 2017 Pescitelli L.; Gianotta M.; Ricceri F.; Lazzeri L.; Milla M.; Prignano F.
Correlation of Ultrasound Scores with Endoscopic Activity in Crohn's Disease: A Prospective Exploratory Study 2023 Dragoni, Gabriele; Gottin, Matteo; Innocenti, Tommaso; Lynch, Erica Nicola; Bagnoli, Siro; Macrì, Giuseppe; Bonanomi, Andrea Giovanni; Orlandini, Beatrice; Rogai, Francesca; Milani, Stefano; Galli, Andrea; Milla, Monica; Biagini, Maria Rosa
Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry 2022 Tapete G, Bertani L, Pieraccini A, Lynch EN, Giannotta M, Morganti R, Biviano I, Naldini S, Mumolo MG, De Nigris F, Calella F, Bagnoli S, Minciotti M, Maltinti S, Rentini S, Ceccarelli L, Lionetti P, Milla M, Costa F.
Increased Risk of Liver Cirrhosis during Azathioprine Therapy for Crohn's Disease 2020 Roselli, Jenny; Innocenti, Tommaso; Lynch, Erica Nicola; Parisio, Laura; Macrì, Giuseppe; Milla, Monica; Mello, Tommaso; Galli, Andrea; Milani, Stefano; Tarocchi, Mirko
Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease 2021 Innocenti, Tommaso; Roselli, Jenny; Lynch, Erica N; Apolito, Pasquale; Parisio, Laura; Bagnoli, Siro; Macrì, Giuseppe; Rogai, Francesca; Tarocchi, Mirko; Milani, Stefano; Galli, Andrea; Milla, Monica; Dragoni, Gabriele
Infliximab is more effective than cyclosporine as a rescue therapy for acute severe ulcerative colitis: a retrospective single-center study 2021 Grazie, Marco Le; Bagnoli, Siro; Dragoni, Gabriele; Caini, Saverio; Annese, Vito; Innocenti, Tommaso; Deiana, Simona; Manetti, Natalia; Milani, Stefano; Galli, Andrea; Milla, Monica
Pregnancy outcomes in inflammatory bowel disease: Data from a large cohort survey 2022 Innocenti, Tommaso; Roselli, Jenny; Taylor, Alice; Dragoni, Gabriele; Lynch, Erica Nicola; Campani, Claudia; Gottin, Matteo; Bagnoli, Siro; Macrì, Giuseppe; Rogai, Francesca; Milani, Stefano; Galli, Andrea; Milla, Monica
Stevens-Johnson Syndrome and Herpes Simplex Type 1 Infection during Adalimumab Therapy for Crohn's Disease 2020 Roselli, Jenny; Innocenti, Tommaso; Lynch, Erica Nicola; Parisio, Laura; Apolito, Pasquale; Mello, Tommaso; Macrì, Giuseppe; Milla, Monica; Biagini, Maria Rosa; Tarocchi, Mirko; Milani, Stefano; Galli, Andrea
The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders 2018 Nencini F.; Vultaggio A.; Pratesi S.; Cammelli D.; Milla M.; Fiori G.; Bagnoli S.; Prignano F.; Romagnani S.; Maggi E.; Matucci A.
Thrombosis in inflammatory bowel diseases: What's the link? 2015 Giannotta, Martina*; Tapete, Gherardo; Emmi, Giacomo; Silvestri, Elena; Milla, Monica